ISPY1 Dataset Sample Clauses

ISPY1 Dataset. This dataset contains the clinical and MRI data from the ISPY1 clinical trial of patients with breast cancer2. The goal of this project was to improve the prediction of clinical outcomes to neoadjuvant chemotherapy in patients with breast cancer. Currently, most patients with breast cancer undergo neoadjuvant chemotherapy, which is aimed to reduce the tumor size (burden) before surgery to remove the tumor or the entire breast. Some of the patients response completely to the therapy and the patient does not present any residual tumor at the time of surgery. On the other hand, some patients have residual disease at the time of surgery and further treatment is required. Dataset Name ISPY1_Trial Owner organization This shared data set was provided by Xxxxx Xxxxxx, PhD and Xxxx Xxxxxx, PhD from the Breast Imaging Research Program at UCSF, in collaboration with XXXXX, CALGB, the I-SPY TRIAL, and TCIA. Dataset description Dataset description (informal meta-data) The dataset includes data about 222 patients treated for breast cancer including demographics, clinical measures and outcomes It is a dataset that was already available when the BOUNCE project started. The data will be explored for their potential to be used in the project for building an in-silico model for resilience prediction. Formal Meta-data There is a data dictionary available for the various columns used. Standards No specific standards have been followed. Origin The I-SPY TRIAL Language The data are numeric Size 13 KB Variety Fully structured Type Numeric Format Tabular format Velocity 1 CSV/XLS file 2 xxxxx://xxxx.xxxxx/xxxxx/ispy-1-trial Storage A copy of the data is available at the BOUNCE data infrastructure Quality High quality data, will not many missing values. In addition a quality and consistency check has already been performed by the owning institution. Example xxxxx://xxxx.xxxxx/xxxxx/ispy-1- trial/workspace/file?filename=clean_data_ISPY-1_clinica.csv Data sharing and ownership Availability The whole dataset is available to the public through their download site. Through the BOUNCE platform, the data will not be made available to external entities. Availability after the end of the project The data will be available after the end of the BOUNCE project both internally in the BOUNCE platform for consortium members and through the original dataset’s website. Sharing mechanisms Data are accessible through the original data web site. Within BOUNCE data are accessible through the Data Acces...
Sample 1
AutoNDA by SimpleDocs
ISPY1 Dataset. This dataset contains the clinical and MRI data from the ISPY1 clinical trial of patients with breast cancer6. The goal of this project is to improve the prediction of clinical outcomes to neoadjuvant chemotherapy in patients with breast cancer. Currently, most patients with breast cancer undergo neoadjuvant chemotherapy, which is aimed to reduce the tumor size (burden) before surgery to remove the tumor or the entire breast. Some of the patients response completely to the therapy and the patient does not present any residual tumor at the time of surgery. On the other hand, some patients have residual disease at the time of surgery and further treatment is required. Table 9 presents the various fields of the dataset. Table 9. Data fields available for the ISPY dataset Data Field Description Value CLINICAL DATA PATIENT DEMOGRAPHICS Age Patient Age Numeric Race_id Patient Race  1=Caucasian  3=African American  4=Asian  5=Native Hawaiian/Pacific Islander  6=American Indian/Alaskan Native  50=Multiple race ON-STUDY DATA (PRE-TREATMENT) ERpos Estrogen Receptor Status (Xxxxxx  0=Negative Score or Community  1=Positive determined), pre-treatment  2=Indeterminate PgRpos Progesterone Receptor Status  0=Negative (Xxxxxx Score or Community  1=Positive determined), pre-treatment  2=Indeterminate HR Pos Hormone Receptor Status, pre- treatment    0=Negative for both ER and PR 1=Positive if either ER or PR was Positive 2=Indeterminate if both ER and PR were Indeterminate Her2MostPos Her2 Status, pre-treatment,  0=Negative (replaced Her2CommPos, adding in Central Her2 IHC results for missing Community   1=Positive Blank= indeterminate or 4/6/2016) Status not done 6 xxxxx://xxxx.xxxxx/xxxxx/ispy-1-trial HR_HER2_CATEGORY 3-level HR/Her2 category pre-  1=HR Positive, Her2 treatment Negative  2=Her2 Positive  3=Triple Negative HR_HER2_STATUS 3-level HR/Her2 status pre- treatment    HRposHER2neg = HR Positive, Her2 Negative HER2pos = Her2 Positive TripleNeg =Triple Negative BilateralCa Does the patient have bilateral  0=No breast cancer prior to  1=Yes neoadjuvant therapy? Laterality Index Tumor Laterality:   1=Left  2=Right IMAGING DATA MRI LD: LD spans all disease present (inv & DCIS) even if there is intervening normal tissue Numeric (in mm) Baseline Timepoint 1= baseline Numeric 1-3d AC Timepoint 2= 1-3days after start of AC Numeric InterReg Timepoint 3= Inter-regimen Numeric PreSurg Timepoint 3= Inter-regimen Numeric OUTCOME DATA SUBJECTID I-S...
Sample 1

Related to ISPY1 Dataset

  • SERVICE MONITORING, ANALYSES AND ORACLE SOFTWARE 11.1 We continuously monitor the Services to facilitate Oracle’s operation of the Services; to help resolve Your service requests; to detect and address threats to the functionality, security, integrity, and availability of the Services as well as any content, data, or applications in the Services; and to detect and address illegal acts or violations of the Acceptable Use Policy. Oracle monitoring tools do not collect or store any of Your Content residing in the Services, except as needed for such purposes. Oracle does not monitor, and does not address issues with, non-Oracle software provided by You or any of Your Users that is stored in, or run on or through, the Services. Information collected by Oracle monitoring tools (excluding Your Content) may also be used to assist in managing Oracle’s product and service portfolio, to help Oracle address deficiencies in its product and service offerings, and for license management purposes.

  • Data Encryption Contractor must encrypt all State data at rest and in transit, in compliance with FIPS Publication 140-2 or applicable law, regulation or rule, whichever is a higher standard. All encryption keys must be unique to State data. Contractor will secure and protect all encryption keys to State data. Encryption keys to State data will only be accessed by Contractor as necessary for performance of this Contract.

  • MSAA Indicator Technical Specification Document This Agreement shall be interpreted with reference to the MSAA Indicator Technical Specifications document.

  • Evaluation Software If the Software is an evaluation version or is provided to You for evaluation purposes, then, unless otherwise approved in writing by an authorized representative of Licensor, Your license to use the Software is limited solely for internal evaluation purposes in non-production use and in accordance with the terms of the evaluation offering under which You received the Software, and expires 90 days from installation (or such other period as may be indicated within the Software). Upon expiration of the evaluation period, You must discontinue use of the Software, return to an original state any actions performed by the Software, and delete the Software entirely from Your system and You may not download the Software again unless approved in writing by an authorized representative of Licensor. The Software may contain an automatic disabling mechanism that prevents its use after a certain period of time. RESTRICTIONS

  • API If the Software offers integration capabilities via an API, your use of the API may be subject to additional costs or Sage specific policies and terms and conditions (which shall prevail in relation to your use of the API). You may not access or use the API in any way that could cause damage to us or the Software, or in contravention of any applicable laws. We reserve the right in our sole discretion, to: (i) update any API from time to time; (ii) place limitations around your use of any API; and (iii) deny you access to any API in the event of misuse by you or to otherwise protect our legitimate interests.

  • Product Data Illustrations, standard schedules, performance charts, instructions, brochures, diagrams, and other information furnished by Developer to illustrate a material, product, or system for some portion of the Work.

  • SHOP DRAWINGS, PRODUCT DATA AND SAMPLES 4.12.1 Shop Drawings are drawings, diagrams, schedules and other, data specially prepared for the Work by the Contractor or any Subcontractor, manufacturer, supplier or distributor to illustrate some portion of the Work.

  • Technical Data For the purpose of this Agreement, "TECHNICAL DATA" shall mean all information of the Company in written, graphic or tangible form relating to any and all products which are developed, formulated and/or manufactured by the Company, as such information exists as of the Effective Date or is developed by the Company during the term hereof.

  • Meteorological Data Reporting Requirement (Applicable to wind generation facilities only) The wind generation facility shall, at a minimum, be required to provide the Transmission Provider with site-specific meteorological data including: • Temperature (degrees Fahrenheit) • Wind speed (meters/second) • Wind direction (degrees from True North) • Atmosphere pressure (hectopascals) • Forced outage data (wind turbine and MW unavailability)

  • Data Analysis In the meeting, the analysis that has led the College President to conclude that a reduction- in-force in the FSA at that College may be necessary will be shared. The analysis will include but is not limited to the following: ● Relationship of the FSA to the mission, vision, values, and strategic plan of the College and district ● External requirement for the services provided by the FSA such as accreditation or intergovernmental agreements ● Annual instructional load (as applicable) ● Percentage of annual instructional load taught by Residential Faculty (as applicable) ● Fall Full-Time Student Equivalent (FFTE) inclusive of dual enrollment ● Number of Residential Faculty teaching/working in the FSA ● Number of Residential Faculty whose primary FSA is the FSA being analyzed ● Revenue trends over five years for the FSA including but not limited to tuition and fees ● Expenditure trends over five years for the FSA including but not limited to personnel and capital ● Account balances for any fees accounts within the FSA ● Cost/benefit analysis of reducing all non-Residential Faculty plus one Residential Faculty within the FSA ● An explanation of the problem that reducing the number of faculty in the FSA would solve ● The list of potential Residential Faculty that are at risk of layoff as determined by the Vice Chancellor of Human Resources ● Other relevant information, as requested

Time is Money Join Law Insider Premium to draft better contracts faster.